News
ESALF
28.00
NaN%
--
Eisai Co (ESALF) Receives a Hold from Goldman Sachs
TipRanks · 15m ago
Weekly Report: what happened at ESALF last week (0608-0612)?
Weekly Report · 26m ago
Weekly Report: what happened at ESALF last week (0601-0605)?
Weekly Report · 06/08 10:21
Weekly Report: what happened at ESALF last week (0525-0529)?
Weekly Report · 06/01 10:26
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), M3 (OtherMTHRF) and Eisai Co (OtherESALF)
TipRanks · 05/28 12:22
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
Seeking Alpha · 05/26 12:11
Weekly Report: what happened at ESALF last week (0518-0522)?
Weekly Report · 05/25 10:29
Eisai Earnings Call Highlights LEQEMBI-Led Growth
TipRanks · 05/20 07:37
Weekly Report: what happened at ESALF last week (0511-0515)?
Weekly Report · 05/18 10:29
Eisai’s E2086 Narcolepsy Trial Adds Quiet Upside Optionality for ESALF Investors
TipRanks · 05/14 16:32
Eli Lilly Alzheimer's drug donanemab launched in India
Seeking Alpha · 05/13 14:57
Weekly Report: what happened at ESALF last week (0504-0508)?
Weekly Report · 05/11 10:26
Biogen says FDA extends review of Leqembi alzheimer’s injection
Seeking Alpha · 05/08 06:52
Weekly Report: what happened at ESALF last week (0427-0501)?
Weekly Report · 05/04 10:23
Biogen trims full-year earnings outlook on BD impact
Seeking Alpha · 04/29 10:34
Eisai’s E6742 Lupus Trial Advances: What ESALF Investors Need to Know
TipRanks · 04/28 16:31
Weekly Report: what happened at ESALF last week (0420-0424)?
Weekly Report · 04/27 10:26
Eisai’s Lenvatinib Combo Trial in Liver Cancer Reaches Completion: What Investors Should Watch Next
TipRanks · 04/23 16:31
Amyloid Setback; Future Possibilities For The Treatment Of Alzheimer's Disease
Seeking Alpha · 04/21 14:48
Merck, Eisai face setback in late-stage trial for Keytruda regimen in kidney cancer
Seeking Alpha · 04/21 11:36
More
Webull provides a variety of real-time ESALF stock news. You can receive the latest news about Eisai Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ESALF
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.